AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.

Guideline ID: 760 Published: 2023 Dec 1

American Association for the Study of Liver Diseases (AASLD)

Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023 Dec 1;78(6):1922-1965. [339 references] *PubMed*

View Original Guideline

Overview

Guideline Objective

To provide an updated approach to the prevention, diagnosis, and treatment of hepatocellular carcinoma (HCC)

Patient Population

Patients with suspected or confirmed HCC

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Risk stratification and prevention measures, including public health policies, hepatitis B (HBV) vaccine, antivirals, and lifestyle interventions
- Guidance on surveillance testing and programs, including ultrasound with or without alpha-fetoprotein (AFP)
- Staging and diagnostic evaluation with biopsy or imaging
- Treatment approaches, including surgical resection, liver transplantation, ablation, transarterial therapies (i.e., chemoembolization, radioembolization), and systemic first-, second-, and beyond-line therapies
- Consideration for advanced care planning

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Erratum; 2023 Dec 1.
- Critical Update; 2025 Feb 24.
- AASLD Policy on Development and Use of Practice Guidelines, Guidances, and Position Papers.

Implementation Tools

- Visual Brief.
- Liver*Learning*® website.

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI